| Recruiting | A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | 2026-03-20 |
| Recruiting | HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor Solid Tumors, Adult | Phase 1 / Phase 2 | 2026-03-04 |
| Recruiting | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors Solid Tumors, Adult | Phase 1 / Phase 2 | 2025-12-16 |
| Completed | Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets Healthy | Phase 1 | 2025-12-11 |
| Completed | Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans Healthy | Phase 1 | 2025-10-28 |
| Recruiting | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations Gliomas Harboring IDH1 and/or IDH2 Mutations | Phase 1 | 2025-07-15 |
| Recruiting | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer Advanced Endometrial Cancer | Phase 3 | 2024-12-12 |
| Completed | Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subje Mass Balance Study | Phase 1 | 2024-11-26 |
| Active Not Recruiting | Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | 2024-11-05 |
| Recruiting | A Clinical Study of HMPL-506 in Patients With Hematological Malignancies Hematological Malignancies | Phase 1 | 2024-05-27 |
| Recruiting | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclit Metastatic Pancreatic Cancer | Phase 2 / Phase 3 | 2024-05-08 |
| Recruiting | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 3 | 2024-04-26 |
| Withdrawn | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases | Phase 1 | 2024-04-02 |
| Recruiting | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2023-07-06 |
| Completed | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study Intrahepatic Cholangiocarcinoma | Phase 1 | 2023-03-17 |
| Completed | A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma Relapsed/Refractory Lymphoma | Phase 2 | 2023-02-13 |
| Completed | Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects Imumune Thrombocytopenia(ITP) Human Mass Balance | Phase 1 | 2023-02-08 |
| Completed | HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study Relapsed or Refractory Lymphoma | Phase 1 | 2022-11-04 |
| Active Not Recruiting | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2 Advanced Renal Cell Carcinoma | Phase 2 / Phase 3 | 2022-10-27 |
| Completed | Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma Relapsed/Refractory Follicular Lymphoma With EZH2 | Phase 2 | 2022-07-29 |
| Completed | A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm Advanced Tumors | Phase 1 | 2022-07-15 |
| Completed | HMPL-523 Food Effect and Proton Pump Inhibitor Study Relapsed or Refractory Lymphoma | Phase 1 | 2022-07-13 |
| Completed | HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI Relapsed or Refractory Lymphoma | Phase 1 | 2022-06-01 |
| Completed | Fruquintinib Renal Impairment Study Renal Impairment | Phase 1 | 2022-03-11 |
| Completed | Fruquintinib Hepatic Impairment Study Hepatic Impairment | Phase 1 | 2022-03-11 |
| Completed | Fruquintinib DDI Study With P-gp and BCRP Substrates Metastatic Colorectal Cancer | Phase 1 | 2022-03-02 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL CLL/SLL, NHL, MCL | Phase 1 | 2022-02-15 |
| Completed | HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma B-Cell Non-Hodgkin's Lymphoma | Phase 1 | 2022-01-04 |
| Completed | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Solid Tumor, Lymphoma, Osteosarcoma | Phase 1 / Phase 2 | 2021-11-30 |
| Completed | Open-label Study of Surufatinib in Japanese Patients Neuroendocrine Tumors, Non-hematologic Malignancy | Phase 1 / Phase 2 | 2021-09-02 |
| Terminated | Open-Label Surufatinib in European Patients With NET Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET | Phase 2 | 2021-08-13 |
| Terminated | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult | Phase 1 / Phase 2 | 2021-08-09 |
| Completed | A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2021-05-27 |
| Terminated | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Isocitrate Dehydrogenase Gene Mutation | Phase 1 | 2021-04-12 |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | 2021-03-05 |
| Terminated | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Isocitrate Dehydrogenase Gene Mutation | Phase 1 | 2021-02-28 |
| Recruiting | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult | Phase 2 / Phase 3 | 2020-09-03 |
| Terminated | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Non Hodgkin Lymphoma | Phase 1 | 2019-09-26 |
| Terminated | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Lymphoma | Phase 1 | 2019-08-26 |
| Completed | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2019-04-25 |
| Completed | A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients Patient Safety | — | 2019-04-20 |
| Completed | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors Tumors | Phase 1 / Phase 2 | 2015-11-01 |
| No Longer Available | Expanded Access Program of Surufatinib Neuroendocrine Tumors | — | — |